VN-0102 / Daiichi Sankyo - LARVOL DELTA

Comparative long-term follow-up study of persistence of immunity after JVC-001 measles, mumps, and rubella vaccination in Japanese children. (PubMed, Hum Vaccin Immunother) - "The results suggested that protective serum antibodies are maintained until the second dose of MMR vaccine is administered in a Japanese pediatric population. Trial registration: jRCTs031230590."

Clinical • Journal • Infectious Disease • Measles • Mumps • Pediatrics • Rubella

Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children. (PubMed, Vaccine) - "Although the non-inferiority of JVC-001 to currently approved vaccines was not demonstrated for the mumps component, clinical significance and consistent efficacy were indicated. Vaccine titer did not affect immunogenicity. JVC-001 is expected to have a lower risk of aseptic meningitis to currently approved vaccines and raised no new safety signals emerged."

Head-to-Head • Journal • CNS Disorders • Infectious Disease • Measles • Mumps • Rubella

Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years. (PubMed, J Infect Chemother) - "The second MMR vaccination with JVC-001 demonstrated sufficient antibody coverage against all three viruses; the safety profile was tolerable."

Journal • P3 data • Infectious Disease • Measles • Mumps • Rubella

Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial. (PubMed, Hum Vaccin Immunother) - "There was no apparent difference in the incidence of AEs between JVC-001 and the control groups. JVC-001 is safe and induces effective immunogenicity against measles, mumps, and rubella compared with the currently marketed vaccines in Japan."

Clinical • Journal • P1/2 data